Incyte scrapped its Phase 1 JAK2V617F inhibitor, INCB160058, after reviewing available data on safety, efficacy, and pharmacokinetics. The company said it “prioritize[s] its next-generation JAK2V617F pipeline,” signaling a pivot away from the earlier candidate’s development path. On its earnings call, Incyte acknowledged concerns about bioavailability and target coverage for the program. The company reiterated that JAK2V617F remains a key therapeutic target and said it expects to share preclinical data later this year for newer replacements. The decision arrives as Incyte continues to invest in oncology portfolio moves, including prior pipeline licensing and acquisition strategy to cover patent-expiration risk.